Ftse Mib
34.186,18
0,07%
DAX
19.909,14
-0,25%
S&P 500
5.912,97
0,10%
NASDAQ
19.509,00
0,11%
Bitcoin
95.067,98
2,60%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Aileron Therapeutics Inc (ALRN) Aileron Therapeutics Inc (ALRN) Notizie

ALRN

Aileron Therapeutics (ALRN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALRN
DataOraFonteTitoloSimboloCompagnia
09/12/202422:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALRNAileron Therapeutics Inc
14/11/202422:15PR Newswire (US)Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:ALRNAileron Therapeutics Inc
14/11/202422:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALRNAileron Therapeutics Inc
13/11/202413:00PR Newswire (US)Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)NASDAQ:ALRNAileron Therapeutics Inc
31/10/202412:30PR Newswire (US)Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for RetinoblastomaNASDAQ:ALRNAileron Therapeutics Inc
12/10/202415:00PR Newswire (US)Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway FibrosisNASDAQ:ALRNAileron Therapeutics Inc
23/09/202413:30PR Newswire (US)Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)NASDAQ:ALRNAileron Therapeutics Inc
21/08/202422:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALRNAileron Therapeutics Inc
19/08/202422:05PR Newswire (US)Aileron Therapeutics to Present at the 8th Annual IPF SummitNASDAQ:ALRNAileron Therapeutics Inc
15/08/202400:05PR Newswire (US)Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsNASDAQ:ALRNAileron Therapeutics Inc
30/07/202414:00PR Newswire (US)Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:ALRNAileron Therapeutics Inc
26/07/202422:33Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALRNAileron Therapeutics Inc
09/07/202414:41Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ALRNAileron Therapeutics Inc
09/07/202414:36Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ALRNAileron Therapeutics Inc
09/07/202414:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ALRNAileron Therapeutics Inc
01/07/202414:00PR Newswire (US)Aileron Therapeutics to be Included in the Russell Microcap® IndexNASDAQ:ALRNAileron Therapeutics Inc
16/05/202423:19Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALRNAileron Therapeutics Inc
15/05/202423:13GlobeNewswire Inc.Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:ALRNAileron Therapeutics Inc
06/05/202422:05GlobeNewswire Inc.Aileron Therapeutics to Present at Two Upcoming Investor ConferencesNASDAQ:ALRNAileron Therapeutics Inc
03/05/202422:05GlobeNewswire Inc.Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 MillionNASDAQ:ALRNAileron Therapeutics Inc
01/05/202414:45GlobeNewswire Inc.Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 MillionNASDAQ:ALRNAileron Therapeutics Inc
01/05/202414:30GlobeNewswire Inc.Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)NASDAQ:ALRNAileron Therapeutics Inc
15/04/202423:20GlobeNewswire Inc.Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:ALRNAileron Therapeutics Inc
12/03/202413:00GlobeNewswire Inc.Aileron Therapeutics Announces CEO TransitionNASDAQ:ALRNAileron Therapeutics Inc
15/02/202422:05GlobeNewswire Inc.Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader EventNASDAQ:ALRNAileron Therapeutics Inc
06/02/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ALRNAileron Therapeutics Inc
05/02/202419:20Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALRNAileron Therapeutics Inc
01/02/202422:30GlobeNewswire Inc.Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024NASDAQ:ALRNAileron Therapeutics Inc
29/01/202422:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALRNAileron Therapeutics Inc
29/01/202422:10Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALRNAileron Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALRN

La tua Cronologia

BIT
ENI
Eni
BIT
STLAM
Stellantis NV
BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STMMI
ST Microelectronics
BIT
TIT
Telecom Italia
BIT
RACE
Ferrari NV
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
TEN
Tenaris
BIT
CPR
Davide Campari
BIT
MONC
Moncler
BIT
SPM
Saipem
BIT
LDO
Leonardo
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network